BioNexus Gene Lab (BGLC) Price to Earnings (2021 - 2026)

BioNexus Gene Lab has disclosed Price to Earnings across 6 years of filings, most recently posting 12.64 for Q2 2026.

• In Q2 2026, Price to Earnings fell 42.37% year-over-year to 12.64; the TTM figure through Jun 2026 stood at 1.41 (up 24.61% YoY), while the FY2025 annual figure was 2.46, up 21.28% from the prior year.
• Price to Earnings came in at 12.64 for Q2 2026 at BioNexus Gene Lab, down from 7.31 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 17155.24 in Q1 2022 to a low of 2378.96 in Q3 2022.
• Average Price to Earnings over 5 years is 710.14, with a median of 8.09 recorded in 2026.
• The largest YoY upside for Price to Earnings was 1516.28% in 2022 against a maximum downside of 447.75% in 2022.
• Over 5 years, Price to Earnings stood at 2508.45 in 2022, then slumped by 98.94% to 26.64 in 2023, then slumped by 153.77% to 14.32 in 2024, then jumped by 50.58% to 7.08 in 2025, then plunged by 78.56% to 12.64 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 12.64 in Q2 2026, 7.31 in Q1 2026, and 7.08 in Q4 2025.